Abstract: The present invention relates to a process for preparing enantiomerically enriched citalopram via methylating enantiomerically enriched didesmethylcitalopram, which is prepared by directly resolving racemic didesmethylcitalopram using a chiral acid.
Type:
Application
Filed:
November 12, 2004
Publication date:
January 15, 2009
Applicants:
DR. REDDY'S LABORATORIES, INC., DR. REDDY'S LABORATORIES LTD.
Abstract: A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying.
Abstract: A coprecipitate comprising amorphous aprepitant and a pharmaceutically acceptable carrier is prepared by rapidly removing solvent from a solution containing aprepitant and the carrier.
Type:
Application
Filed:
July 31, 2006
Publication date:
September 4, 2008
Applicants:
DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.
Abstract: The invention relates to extended release pharmaceutical compositions of venlafaxine or pharmaceutically acceptable salts. More particularly this invention relates to a pharmaceutical composition having a core comprising venlafaxine and a coating thereupon. The coating utilizes at least one water insoluble polymer and at least one polymer having pH dependent solubility to delay and modulate the release of the drug in an extended manner.
Type:
Application
Filed:
July 28, 2006
Publication date:
August 14, 2008
Applicants:
DR. REDDY'S LABORATORIES LTD., DR. REDDY'S LABORATORIES, INC.
Abstract: The present invention relates to novel oxazolidinone compounds of formula (I), their stereoisomers, their salts and pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their stereoisomers, their salts and pharmaceutical compositions.
Type:
Grant
Filed:
July 3, 2003
Date of Patent:
January 9, 2007
Assignees:
Dr.Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.
Abstract: The present invention relates to novel crystalline forms of Amlodipine Maleate These crystalline forms are useful as pharmaceutical agents. This invention also relates to pharmaceutical compositions which include these crystalline forms and to methods of treatment using these crystalline forms. The novel crystalline compounds of the present invention are useful as calcium channel blockers and are thus useful as anti-ischaemic and anti-hypertensive agents.
Abstract: The present invention relates to novel oxazolidinone compounds of formula (I), their stereoisomers, their salts and pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their stereoisomers, their salts and pharmaceutical compositions.
Type:
Application
Filed:
August 29, 2006
Publication date:
January 4, 2007
Applicants:
Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.
Abstract: The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel ?-aryl-?-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
Type:
Grant
Filed:
December 7, 2005
Date of Patent:
January 2, 2007
Assignees:
Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.
Abstract: The present invention relates to novel oxazolidinone compounds of formula (I), their stereoisomers, their salts and pharmaceutical compositions containing them. The present invention also relates to a process for the preparation of the above said novel compounds, their stereoisomers, their salts and pharmaceutical compositions.
Type:
Application
Filed:
August 29, 2006
Publication date:
December 28, 2006
Applicants:
Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories, Inc.
Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
Abstract: Compounds of formula (I) its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates can be used to prevent or treat diabetes caused by insulin resistance or impaired glucose tolerance or complications of diabetes caused by insulin resistance or impaired glucose tolerance. The compounds can also be used to reduce cholesterol, body weight, blood glucose, triglycerides and free fatty acids in the blood.
Abstract: A method for preventing or treating complications of diabetes by administering a compound of formula (I)
its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts or its pharmaceutically acceptable solvates.
Abstract: The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Type:
Grant
Filed:
December 26, 2001
Date of Patent:
August 24, 2004
Assignees:
Dr. Reddy's Laboratories Ltd., Dr. Reddy's Laboratories Inc.
Abstract: The present invention relates to novel antidiabetic compounds, their tautomeric forms, their derivatives, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. This invention particularly relates to novel azolidinedione derivatives of the general formula (I), and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them.
Abstract: The present invention relates to an improved process for the preparation of novel antidiabetic compounds having formula (1) where R1 represents hydrogen or lower alkyl group and X represents hydrogen or halogen atom.
Abstract: The present invention relates to novel hypolipidemic, antihyperglycemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel &bgr;-aryl-&agr;-oxysubstituted alkylcarboxylic acids of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
Abstract: The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
Abstract: The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.